ResMed (RMD) Q3 2025 10-Q Quarterly Report

Filed: Oct 31, 2025Period ending Sep 30, 2025

Health Care

Surgical & Medical Instruments & ApparatusSEC EDGAR

ResMed (RMD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 31, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

ResMed Q3 2025 10-Q Analysis

Risk Factors

• No material changes to risk factors since the fiscal year 2025 10-K filing

ResMed Q3 2025 Quarterly Financials
XBRL

Revenue

$1.3B

▲ +9.1% YoY

Net Income

$349M

▲ +11.9% YoY

Net Margin

26.1%

▲ +67bp YoY

Source: XBRL data from ResMed Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other ResMed Quarterly Reports

Q4 2025 10-Q

Q1 2025 10-Q

Get deeper insights on ResMed

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.